CD8A and neoplasm: The data suggest that: (1) Imiquimod enhances antigen presentation and activates the T cell compartment; (2) Triple therapy efficacy requires cross-priming of antitumor CD8+ T cells; (3) Triple therapy dramatically increases the number of gp100 tetramer-positive CD8+ tumor infiltrating lymphocytes; and (4) Triple therapy modulates expression of genes associated with immune signaling cascades and pigmentation.